MC

556.9

-3.33%↓

SANES

6.177

-1.92%↓

BNP

75.4

-1.39%↓

CS.FR

39.95

-0.77%↓

ALV

356.3

+0.06%↑

MC

556.9

-3.33%↓

SANES

6.177

-1.92%↓

BNP

75.4

-1.39%↓

CS.FR

39.95

-0.77%↓

ALV

356.3

+0.06%↑

MC

556.9

-3.33%↓

SANES

6.177

-1.92%↓

BNP

75.4

-1.39%↓

CS.FR

39.95

-0.77%↓

ALV

356.3

+0.06%↑

MC

556.9

-3.33%↓

SANES

6.177

-1.92%↓

BNP

75.4

-1.39%↓

CS.FR

39.95

-0.77%↓

ALV

356.3

+0.06%↑

MC

556.9

-3.33%↓

SANES

6.177

-1.92%↓

BNP

75.4

-1.39%↓

CS.FR

39.95

-0.77%↓

ALV

356.3

+0.06%↑

Search

Ipsen SA.

Abierto

SectorFinanzas

108.8 2.74

Resumen

Variación precio

24h

Actual

Mínimo

105.5

Máximo

109.6

Métricas clave

By Trading Economics

Ingresos

-118M

114M

Ventas

71M

1.8B

P/B

Media del Sector

24.918

22.015

Rentabilidad por dividendo

1.12

Margen de beneficio

6.249

Empleados

5,358

EBITDA

228M

710M

Recomendaciones

By TipRanks

Recomendaciones

Neutral

Estimación a 12 meses

+16.14% upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

1.12%

3.90%

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

8.8B

Apertura anterior

106.06

Cierre anterior

108.8

Noticias sobre sentimiento de mercado

By Acuity

44%

56%

191 / 542 Clasificación en Finance

Puntuación técnica

By Trading Central

Confianza

Bearish Evidence

Ipsen SA. Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

10 dic 2024, 07:05 UTC

Charlas de Mercado

EU Specialty Pharma to See Product Launches But Limited Clinical Data Next Year -- Market Talk

Comparación entre iguales

Cambio de precio

Ipsen SA. Esperado

Precio Objetivo

By TipRanks

16.14% repunte

Estimación a 12 meses

Media 123.57 EUR  16.14%

Máximo 145 EUR

Mínimo 110 EUR

De acuerdo con 7 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Ipsen SA. Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

7 ratings

2

Comprar

4

Mantener

1

Vender

Puntuación técnica

By Trading Central

105.5 / 108.6Soporte y Resistencia

Corto Plazo

Bearish Evidence

Medio plazo

Strong Bearish Evidence

Largo Plazo

Bearish Evidence

Sentimiento

By Acuity

191 / 542 Clasificación en Finanzas

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Ipsen SA.

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France.